Sino Biopharmaceutical (1177) Stock Statistics & Valuation Metrics

Sino Biopharmaceutical has a market cap or net worth of $73.82B. The enterprise value is HK$55.37B.

Sino Biopharmaceutical has 18,769,717,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sino Biopharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 9.45%.

The current PE Ratio of Sino Biopharmaceutical is 30.45. Sino Biopharmaceutical’s PEG ratio is -0.43.

In the last 12 months, Sino Biopharmaceutical had revenue of 26.20B and earned 2.33B in profits. Earnings per share was 0.08.

In the last 12 months, operating cash flow was 3.08B and capital expenditures -407.50M, giving a free cash flow of 2.67B billion.

Sino Biopharmaceutical pays an annual dividend of HK$0.039, resulting in a dividend yield of 1.5%

Sino Biopharmaceutical upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.

Sino Biopharmaceutical as a current ratio of 1.05, with Debt / Equity ratio of 29.46%

In the past 12 months, Sino Biopharmaceutical has paid 797.27M in taxes.

Sino Biopharmaceutical EV to EBITDA ratio is 10.62, with an EV/FCF ratio of 17.00.

Sino Biopharmaceutical has $13.18B in cash and marketable securities with ¥198.43M in debt, giving a net cash position of -$3.50B billion.

Gross margin is 82.08%, with operating margin of 22.08%, and net profit margin of 8.90%.

The average price target for Sino Biopharmaceutical is $4.42, which is 11.43% higher than the current price. The consensus rating is Moderate Buy